Oncimmune Expands Application Of Liquid Biopsy Auto-Antibody Technology
Executive Summary
The company’s liquid biopsy test business is complemented by a patient-stratification service for pharmaceutical companies.
You may also be interested in...
Device/Diagnostics Quarterly Dealmaking Statistics, Q1 2019
Device financing totaled $1.6bn for the first quarter of 2019. Late-stage venture rounds were the most active category, led by Nuvaira's $79m Series E financing. Merger and acquisition activity reached $7.3bn; in the largest transaction of the quarter, Ethicon acquired Auris Health for up to $6bn. Diagnostics/research financing reached $1.7bn, and ten diagnostics/research tools companies were acquired, five of which together were valued at $22.6bn.
Biodesix Buys US Laboratory Assets From Oncimmune
Biodesix is expanding its portfolio of lung cancer diagnostic tests and acquiring the US assets of UK company Oncimmune.
Oncimmune Reels In New Strategy Head And More Capital
Oncimmune, the UK specialist in autoantibody-based tests for early cancer detection, has bullked up its human and financial resources with the appointment of a chief medical and strategy officer, and the closing of an investment tranche from its Chinese partner.